Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical, radiographic, and histologic features consistent with the diagnosis of IPF~* SpO2 ≥90% at rest by pulse oximetry while breathing ambient air.~* FVC ≥50% of predicted.~* FEV1 ≥50% of predicted.~* Ratio of FEV1 to FVC ≥0.7.~* DLCO corrected for hemoglobin 30% to 79% of predicted, inclusive.~Exclusion Criteria:~* History of acute exacerbation of IPF or respiratory tract infection within 3 months prior to Screening.~* Planned surgery during the study.~* History of malignant tumor within 5 years prior to Screening.~* History of emphysema or clinically significant respiratory diseases (other than IPF).~* Other known causes of interstitial lung disease (eg, drug toxicities, environmental exposures, connective tissue diseases).~* End-stage fibrotic disease expected to require organ transplantation within 6 months.~* Taking a systemic corticosteroid, cytotoxic therapy, vasodilator therapy for pulmonary hypertension, or unapproved treatment for IPF within 4 weeks prior to Screening. (Treatment with pirfenidone or nintedanib, though not both concurrently, is permitted, provided that the subject has been on a stable dose for at least 4 weeks prior to Screening and it is anticipated the dose will remain unchanged throughout enrollment.)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TRK-250 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).